Literature DB >> 28496667

Stroke Prevention in Atrial Fibrillation.

Michael Katsnelson1, Sebastian Koch1, Tatjana Rundek1.   

Abstract

Non-valvular atrial fibrillation is a common and from a neurological perspective the most significant cardiac arrhythmia with a growing world-wide incidence. It also carries a significant associated morbidity and mortality, with cardioembolic strokes arguably being the most disabling sequelae. This brief review will highlight the important studies and the latest treatment modalities available for stroke prevention in patients with non-valvular atrial fibrillation.

Entities:  

Year:  2010        PMID: 28496667      PMCID: PMC4955901          DOI: 10.4022/jafib.279

Source DB:  PubMed          Journal:  J Atr Fibrillation        ISSN: 1941-6911


  85 in total

Review 1.  Dabigatran challenges warfarin's superiority for stroke prevention in atrial fibrillation.

Authors:  Neil E Schwartz; Gregory W Albers
Journal:  Stroke       Date:  2010-04-15       Impact factor: 7.914

2.  Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF).

Authors:  Brian F Gage; Yan Yan; Paul E Milligan; Amy D Waterman; Robert Culverhouse; Michael W Rich; Martha J Radford
Journal:  Am Heart J       Date:  2006-03       Impact factor: 4.749

3.  Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall.

Authors:  Brian F Gage; Elena Birman-Deych; Roger Kerzner; Martha J Radford; David S Nilasena; Michael W Rich
Journal:  Am J Med       Date:  2005-06       Impact factor: 4.965

4.  Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism.

Authors:  P M Kuijer; B A Hutten; M H Prins; H R Büller
Journal:  Arch Intern Med       Date:  1999-03-08

5.  Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.

Authors:  Robert G Hart; Lesly A Pearce; Maria I Aguilar
Journal:  Ann Intern Med       Date:  2007-06-19       Impact factor: 25.391

6.  Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study.

Authors:  S Stewart; C L Hart; D J Hole; J J McMurray
Journal:  Heart       Date:  2001-11       Impact factor: 5.994

7.  Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Daniel E Singer; Gregory W Albers; James E Dalen; Margaret C Fang; Alan S Go; Jonathan L Halperin; Gregory Y H Lip; Warren J Manning
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

8.  The history of atrial fibrillation: the last 100 years.

Authors:  Eric N Prystowsky
Journal:  J Cardiovasc Electrophysiol       Date:  2008-05-05

9.  New therapeutic option for thromboembolism--dabigatran etexilate.

Authors:  Hitoshi Nishio; Masahiro Ieko; Toru Nakabayashi
Journal:  Expert Opin Pharmacother       Date:  2008-10       Impact factor: 3.889

10.  Occurrence of hemispheric and retinal ischemia in atrial fibrillation compared with carotid stenosis.

Authors:  D C Anderson; L J Kappelle; M Eliasziw; V L Babikian; L A Pearce; H J M Barnett
Journal:  Stroke       Date:  2002-08       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.